Akero Therapeutics Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Akero Therapeutics (AKRO) PT Raised to $75 at Jefferies
January 29, 2025 4:08 PM ESTJefferies analyst Michael Yee raised the price target on Akero Therapeutics (NASDAQ: AKRO) to $75.00 (from $50.00) while maintaining a Buy rating.
The analyst comments "We raise our PT to $75 based on $5-6B cap or $2-3B+ clear oppty in NASH based on strong F4... More
